This review provides an overview of the clinical value of the most relevant renal biomarkers, focusing on two main clinical conditions: acute kidney injury and chronic kidney disease. We categorize biomarkers according to their actionability, in terms of a documented response to treatment in relation to outcomes. Furthermore, we introduce a new category of renal biomarkers, metabolic biomarkers, and underscore their capacity to be highly actionable.
© 2017 American Society for Clinical Pharmacology and Therapeutics.